Trial Profile
A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ad26 Mos HIV (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Vaccines and Prevention B.V
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Planned End Date changed from 3 Jan 2019 to 4 Jan 2019.
- 04 Dec 2018 Status changed to active, no longer recruiting.